Significance statement
Viruses of bacteria (phages) represent the most abundant living entities on the planet, and many aspects of our fundamental knowledge of phage-bacteria relationships remain elusive. Many phages encode specialised small proteins, which modulate essential physiological processes in bacteria in order to convert the bacterial cell into a 'factory' for phage progeny production -ultimately leading to the demise of the bacterial cell. We describe the identification of several antibacterial proteins produced by a prototypical phage that infects Bacillus subtilis and describe how one such protein subverts the protein control system of its host to benefit phage progeny development. The results have broad implications for our understanding of phage-bacteria relationships and the therapeutic application of phages and their gene products.
/body
Much like eukaryotic and archaeal viruses, which derail the host's cellular processes to facilitate viral replication, phages have evolved complex strategies to acquire their bacterial hosts. In order to successfully infect and replicate in the bacterial cell, many phages encode proteins that specifically interfere with essential biological processes of the host bacterium, including transcription, translation, DNA replication and cell division (1) . Phage proteins that interfere with host processes are typically small in size (on average ~160 amino acid residues) and are usually produced at high levels early in the infection cycle (2) . SPO1 is a prototypical lytic phage of Bacillus subtilis and its genes are categorised as early, middle and late to reflect the time of their expression during SPO1 development in B. subtilis. The majority of SPO1 early genes associated with host takeover are in the 12.4 kb terminal region of the genome, which includes the 26-gene host takeover module ( Fig. 1A) (3, 4) .
The genes within the host takeover module, gp37-gp60, have several hallmarks to suit the characteristics of phage proteins that interfere with host processes: They are mostly small, produced early in infection and contain promoters and ribosome binding sites characteristic of highly expressed genes (3, 5) . Many of them have been previously shown to be involved in the shut-off of bacterial DNA and RNA synthesis (gp38, gp39, gp40, gp44, gp50 and gp51) or to inhibit cell division (gp56) during SPO1 infection (6) (7) (8) . Further, plasmid-borne expression of gp44 and gp56 in B. subtilis has been shown to attenuate growth and reduce viability, respectively (8, 9) . With the exception of the product of gp44, which has been postulated to interact with B. subtilis RNA polymerase (9, 10), the bacterial targets and mechanism of action of the gene products encoded by the host takeover module of SPO1 remain elusive. Clearly, phages and their gene products represent an underexploited resource for potentially developing novel antibacterial strategies and to gain new insights into bacterial cell function and regulation. In this study, we undertook a systematic approach to identify genes in the SPO1 phage host takeover module that had a detrimental effect on B. subtilis growth and unveil the biological role of the product of gp53, which interacts with the Hsp100/Clp family member ClpC of B. subtilis.
Results

The effect of SPO1 host takeover module genes on B. subtilis growth
We wanted to identify genes in the SPO1 host takeover module that had a detrimental effect on B.
subtilis growth by growing bacteria in the absence and presence of isopropyl β-D-1thiogalactopyranoside (IPTG), which allowed plasmid pHT01 (11) borne expression of the 26 host takeover genes either individually or with other genes in their respective operons ( Fig. 1A ). Any effect of the gene products of the host takeover module on B. subtilis growth was monitored by determining the cell density by measuring light absorbance of the culture at 600 nm after a 5-hour period of incubation at 37°C ( Fig. 1B) . As the control, we used bacteria containing pHT01 plasmid expressing green fluorescent protein (GFP). As shown in Fig. 1C , when the SPO1 phage host takeover module genes were expressed individually in B. subtilis, the growth of bacteria expressing Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56 and Gp60 was attenuated by 50% or more when compared to the control cells expressing GFP. The individual graphs in Fig. 1D show growth curves of B. subtilis expressing Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56 and Gp60 over a period of 8 hours. We noted that, under our conditions, the plasmid-borne expression of Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56 and Gp60 did not inhibit growth per se but attenuated growth by extending the lag time to varying degrees ( Fig. 1D ). Further, it seemed that leaky expression (which occurs in the absence of the inducer) of Gp53, Gp56 and Gp60 also attenuated growth to some degree, indicating that the latter SPO1 gene products are potentially more toxic to B. subtilis than the others (i.e. Gp37, Gp41, Gp42, Gp44 and Gp46). The expression of the SPO1 host takeover module genes together with other genes in their respective operons revealed that operons containing genes shown to attenuate growth when expressed individually also attenuated growth efficiently ( Fig. 1E ) with the following exceptions: Firstly, Gp38, Gp39 and Gp40 when expressed together in operon 1 and operon 2, appeared to act synergistically and displayed an enhanced ability to attenuate bacterial growth (compare Fig. 1C and. Fig. 1E ). Secondly, we note that in B. subtilis cells in which the host takeover module genes in operon 1, 2 and 7 are expressed together do not recover under our experimental conditions. This indicates that the host takeover module gene products within each operon functionally interact and thus have a more pronounced effect on host physiology than when expressed individually. Finally, we note that Gp46 is no longer able to attenuate growth of B. subtilis when expressed together with Gp45 in operon 3. This implies that the Gp45 somehow mitigates the antagonistic effect of Gp46 on B. subtilis cells. Overall, we conclude that recombinant forms of Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56 and Gp60 have a detrimental effect on B. subtilis growth in the absence of SPO1 infection, presumably by targeting essential cellular processes.
Gp53 interacts with the ClpC ATPase of the ClpCP protease in B. subtilis
Since Gp53 was experimentally better tractable than the other SPO1 host takeover module gene products, we focused on identifying the target(s) of Gp53 in B. subtilis. We constructed an amino (N) terminal hexa-histidine (6His) tagged version of Gp53 to identify its bacterial target(s) by conducting a pull-down assay using whole-cell extracts of exponentially growing B. subtilis cells. Initially, we investigated whether the histidine tagged version of Gp53 retained its ability to attenuate B. subtilis growth under the conditions described in Fig. 1 . As shown in Fig. 2A , the activity of N terminal 6His tagged Gp53 and its untagged counterpart did not differ significantly. For simplicity, from here on the N terminal 6His tagged version of Gp53 will be referred to as Gp53. In order to perform the pulldown assays, purified Gp53 was immobilised onto nickel resin and the 'charged' resin was incubated with whole-cell extracts prepared from exponentially growing B. subtilis cells (Fig. 2B ). The resin was then extensively washed to remove any non-specific interactions before analysis by SDS polyacrylamide gel electrophoresis (PAGE). As shown in Fig. 2C , when the pull-down assay was conducted in the presence of Gp53, we detected a specific enrichment of a band on the SDS-PAGE gel ( To establish that the interaction between Gp53 and ClpC is specific and to identify amino acids in Gp53 important for binding to ClpC, we conducted a BLAST search using standard search parameters and SPO1 Gp53 as a query sequence. Three homologous proteins and 1 protein fragment from SPO1 related phages were found ( Fig. S1 ) with amino acids (L83, V87, R94, L95 and K101) conserved across all five sequences. All these residues were individually substituted with alanine (A), apart from the positively charged residues R94 and K101, which were also replaced with negatively charged glutamic acid (E) residues. Next, a bacterial two-hybrid (BTH) interaction assay was performed to determine how the amino acid substitutions in Gp53 affected its ability to interact with ClpC. We opted for the bacterial adenylate cyclase two-hybrid (BACTH) system in which both genes gp53 and clpC were co-expressed in a Δcya E. coli strain DHM1 as fusions to one of two fragments (T18 and T25) of the catalytic domain of Bordetella pertussis adenylate cyclase (12) . Interaction of two-hybrid proteins results in a functional complementation between T18 and T25 leading to cAMP synthesis, and transcriptional activation of the lactose operon that can be detected in a β-galactosidase assay. As shown in Fig. 2E , reactions with Gp53 variants harbouring an alanine substation at V87A or L95A and charge-reversal substitution at R94 (R94E) displayed significantly lower β-galactosidase activity compared to the reaction with wild-type Gp53. We conclude that proximally located amino acid residues V87, R94 and L95 in Gp53 are important determinants for binding to ClpC.
Gp53 stimulates the ATPase activity of ClpC in an analogous manner to B. subtilis adaptor proteins
The role of ClpC in B. subtilis is the ATP hydrolysis dependent unfolding and loading of substrate proteins for degradation by the protease ClpP. Substrate specificity upon ClpC is conferred by different adaptor proteins, which interact with ClpC and cause ClpC to oligomerise and form a complex with ClpP monomers that come together to form the proteolytic chamber ( Fig. 3A) . In other words, the adaptor protein is an obligatory activator of the ClpCP protease (13) . Since the binding of the adaptor protein, such as the well-documented MecA protein, has been shown to stimulate the basal ATPase activity of ClpC, we initially tested how Gp53 binding affected the ATPase activity of To directly determine that Gp53 competes with MecA for binding to ClpC, we used a modified version of the BTH assay described in Fig subtilis adaptor proteins, it is likely to compete with them for binding to ClpC (see below). Thus, by inference, we suggest that Gp53 could affect the normal functioning of the ClpCP protease by excluding the functionally obligatory adaptor proteins from interacting with it.
Gp53 alters the specificity of the ClpCP protease in B. subtilis
We next investigated the effect of Gp53 on the protease activity of ClpCP. Although adaptor proteins like MecA are required for activation and to confer specificity upon the ClpCP protease, they are degraded along with the substrate or even in the absence of the substrate (15) . Therefore, to determine whether Gp53 inhibits the proteolytic activity of the ClpCP protease or merely alters its specificity during SPO1 development in B. subtilis, we initially tested, using purified components, whether Gp53 is also degraded by the ClpCP protease in the absence of any substrate. As shown in Fig The growth of wild-type and ΔclpC strains under our experimental conditions did not detectably differ ( Fig. 5A) . A rapid drop in cell density, indicating cell lysis, was observed after ∼30 minutes in the wild-type B. subtilis culture infected with SPO1 at OD600 0.2 (Fig. 5B ). As expected, the ΔclpC B. subtilis culture infected with SPO1 continued to grow for a further 20 minutes, reaching a higher cell density than the wild-type strain, before undergoing cell lysis (Fig. 5B ). As shown in Fig. 5C , similar results were obtained with B. subtilis strains containing ClpC which is unable to hydrolyse ATP because of two mutations within the Walker B domain in both ATPase domains (strain IH140 (18)) or efficiently interact with ClpP because of a deletion in a region required for binding to ClpP (VGF::GGR, strain IH217 (22)): In the case of the IH140 and IH217 mutant B. subtilis strains, the culture continued to grow for a further 10 minutes compared to the wild-type culture before cell lysis occurred. Overall, the results are consistent with the findings above and indicate that the altering the specificity of ClpCP protease by Gp53, but not its inhibition, is required for optimal SPO1 development in B. subtilis.
Discussion
A common theme by which phages affect host physiology to benefit phage progeny development is through the modulation or inhibition of bacterial cellular processes (1, 2) . Previous studies (6) (7) (8) (9) revealed that SPO1 infection results in the remodelling of several host processes by six (Gp38, Gp39, Gp40, Gp44, Gp50 and Gp51) of the twenty-six genes encoded by the host takeover module.
Specifically, although the molecular details still remain elusive, Gp38, Gp39, Gp40, Gp44, Gp50 and Gp51 have been implicated in the shut-off of host macromolecular biosynthetic processes (RNA, DNA and protein synthesis) and Gp56 in the inhibition of bacterial cell division (6) (7) (8) . This study revealed that Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56 and Gp60 attenuate the growth of B.
subtilis in the absence of SPO1 infection (Fig. 1 ). It seems that the individual effects of some host takeover module gene products, e.g. Gp38, Gp39, Gp40, might not be sufficient to affect bacterial growth. In support of this view, co-expression of Gp38, Gp39 and Gp40, which constitute operon 2 of the host takeover module (Fig. 1A) , resulted in increased growth attenuation, presumably through synergistic activities of Gp38, Gp39 and Gp40. As phage genomes tend to be compact and efficient, it is remarkable that SPO1 has evolved many elaborate mechanisms to take over B. subtilis cells. We predict that the action of each individual host takeover module gene product is carefully regulated in a temporally coordinated manner and that some functionally interact with each other to bring about the desired effect (e.g. Gp38, Gp39 and Gp40) or control their functionalities. The observation that the co-expression of Gp45 with Gp46 (operon 3) counteracts the effect of the latter on B. subtilis growth (Fig. 1E ) further underscores this view. Further, it is tempting to speculate that genes within operon 3 of the host takeover module are akin to a toxin/anti-toxin module. Further, it is important to remember that most studies on phage-host interactions, like the present one, are conducted under 'optimal' laboratory conditions. Thus, it is possible that some of the SPO1 host takeover module gene products might only be required for infecting and replicating in bacteria in different physiological states e.g. a nutrient starved population of bacteria. For example, Gray et al recently reported that B. subtilis can exist in an oligotrophic state without sporulating (23) . It would thus be interesting to investigate whether some SPO1 host takeover gene product and their targets become essential for SPO1 development under this state of growth. Further, our earlier work on the T7 phage led to the identification of a T7 gene product involved in the inhibition of the bacterial RNAP only in the stationary phase of growth (24) .
Although it is common for phages to depend on or inhibit the host's protein degradation machinery for phage developmental requirements (e.g. lysis-lysogeny decision in phage lambda (25) , DNA replication/transcription decision in phage Mu (26) or inhibition of Lon protease by T4 (27)), to the best of our knowledge, this study presents the only example of a phage protein that alters the substrate specificity of the host's protein degradation machinery to allow optimal phage development.
Under standard laboratory conditions, the absence of ClpCP protease activity had a subtle yet consistent detrimental effect on the efficacy of SPO1 development in B. subtilis (Fig. 5 ). Thus, it is possible that the requirement for the ClpCP protease activity by SPO1 becomes more prominent under more native and/or specific conditions for B. subtilis (see above). The results reveal that SPO1 Gp53 competes with host adaptor protein(s) for binding to ClpC and thereby alters the specificity of the ClpCP protease. Since different adaptor proteins, for example McsB and MecA, can compete for binding to ClpC to confer substrate specificity upon the ClpCP protease (14, 17) and it seems that Gp53 is an example of an adaptor-like protein produced by a phage. Consistent with this view, the results revealed that the binding site of Gp53 on ClpC is likely to overlap with that of native adaptor proteins such as MecA or McsB ( Fig. 3 and Fig. 4 ). Thus, it is conceivable that Gp53 functionally mimics the role of a B. subtilis adaptor protein, which, consequently, could result in the subversion of the ClpCP protease to benefit phage development. We propose the following two mutually exclusive scenarios: (1) that Gp53 could act like an adaptor protein and target SPO1 derived substrates for proteolysis and consequently interferes with the recognition and targeting of "natural" substrates by the native (bacterial) adaptor proteins for proteolysis by the ClpCP protease and/or (2) Gp53 repurposes the ClpCP protease to degrade or protect bacterial substrates in order to benefit SPO1 development. The fact that the ClpCP protease and its adaptor proteins are involved in both regulatory (e.g. transcription factors) and general (misfolded damaged proteins) proteolysis (28) would support the view that a competing 'xenogeneic' adaptor protein such a Gp53 would have detrimental pleiotropic effects on the growth of B. subtilis cells (Fig. 1) .
The ClpC and ClpP proteins of Gram-negative and Gram-positive bacteria have recently been recognised as viable targets for antibiotic discovery and a number of naturally-occurring antibacterial products deregulate the respective activities of ClpC or ClpP resulting in bacterial cell death (29, 30) .
With the emerging interest in the use of phages and phage encoded proteins as source of alternatives to antibiotics, this study reveals that the ClpCP protease of B. subtilis and homologs in other bacteria can be subjected to xenogeneic dysregulation by phage derived factors and adds Gp53 to the growing list of naturally-occurring antibacterial products that target the bacterial protein degradation machinery.
Materials and Methods
Plasmids, strains and proteins. All the plasmids used in this study for protein expression and the BTH assays were generated using standard molecular biology procedures and are detailed in Table   S1 . The pSCBAD-Gp53 was made by Gibson assembly (31): The pSC101 plasmid (32) was modified by inserting the regulatory region of pBAD33 (araC promoter region, multiple cloning site and the rrnB T2 terminator) between restriction sites XhoI and NsiI. All proteins used in this study were purified by either Ni-affinity chromatography (for 6His tagged proteins i.e. Gp53, MecA, and ClpP) or anti-FLAG M2 affinity resin (for FLAG tagged proteins i.e. ClpC) using standard molecular biology procedures. The details of plasmids used for protein purification are shown in Table S1 . All the strains used in this study are shown in Table S2 .
Bacterial growth assays. Unless otherwise stated, B. subtilis cultures were grown in 2xYT medium (Sigma) with 2% (w/v) glucose and appropriate antibiotics at 37 °C. For the experiments shown in Fig. 1 and Fig. 2A , seed cultures were grown at 37 °C, shaking at 700 rpm for 16-18 hours in a THERMOstar (BMG Labtech) plate incubator by directly inoculating a colony into 200 µl of 2xYT medium containing 5 µg/ml chloramphenicol and 2% (w/v) glucose (to prevent leaky expression from pHT01 vector) into a 48-well plate (Greiner). The growth curves were also performed in 48-well plates in a SPECTROstar Nano Absorbance multiwell plate reader (BMG Labtech): the seed cultures were OD600-corrected to 0.025 in 200 µl of fresh 2xYT medium containing 5 µg/ml chloramphenicol, 2% (w/v) glucose, and either water or 1 mM IPTG to induce the expression of SPO1 host takeover genes. Cultures were incubated at 37°C, shaking at 700 rpm. At least three biological and technical replicates were performed.
Pull down assays. These were performed as previously described by (24) using proteins specified in the main text and figures, with the following amendments: binding buffer (25 mM NaH2PO4, 50 mM NaCl, 5 mM imidazole, 5% glycerol at pH 7), wash buffer (25 mM NaH2PO4, 50 mM NaCl, 15 mM imidazole, 5% glycerol at pH 7) and samples were eluted by adding 50 µl of Laemmli 2x concentrate SDS Sample Buffer to beads and boiled for 5 minutes prior to analysis by SDS-PAGE.
Bacterial two-hybrid interaction assays. These were carried out using the Bacterial Adenylate Cyclase-based Two-Hybrid (BACTH) system (Euromedex) and were conducted as per manufacturer's guidelines. Briefly, recombinant plasmids encoding proteins of interest fused to the T25 or T18 domain of adenylate cyclase were transformed into competent DHM1 cells (see Table S1 for details of plasmids used). Transformants were grown in a 96-well plate in LB medium containing ampicillin (100 µg/ml), kanamycin (50 µg/ml), and IPTG (0. ClpCP mediated protein degradation assays. These were conducted exactly as described previously in (15) . The protein components were present at the amounts indicated in the figure legends.
SPO1 infection assays.
Seed cultures of bacteria were grown at 37 °C, shaking at 700 rpm for [16] [17] [18] hours in a THERMOstar (BMG Labtech) plate incubator by directly inoculating a colony into 1 ml of 2xYT medium into a 24-well plate (Greiner). The infection curves were also performed in 24-well plates in a SPECTROstar Nano Absorbance multiwell plate reader (BMG Labtech). The seed cultures were OD600-corrected to 0.05 in 1 ml of fresh 2xYT medium and incubated at 37 °C shaking at 700 rpm. At OD600 0.2 SPO1 lysate was added in a 1:1 ratio of bacterial cells : phage particles and OD600 measurements taken every 10 minutes until full lysis of the bacterial culture occurred. At least three biological and technical replicates were performed. 
Figure legends
